T1	Outcomes 452 460	efficacy
T2	Outcomes 465 471	safety
T3	Outcomes 1666 1695	were HIV-free infant survival
T4	Outcomes 1714 1739	months; HIV-free survival
T5	Outcomes 1778 1807	breastfed; AIDS-free survival
T6	Outcomes 1833 1859	and serious adverse events
T7	Outcomes 1875 1881	babies
T8	Outcomes 2148 2187	The cumulative rate of HIV transmission
T9	Outcomes 2509 2520	(p=0Â·029).
T10	Outcomes 2521 2560	The cumulative rate of HIV transmission
T11	Outcomes 2788 2831	intended to breastfeed, the cumulative rate
T12	Outcomes 2987 3015	single-dose nevirapine group
T13	Outcomes 3087 3114	in a different publication.
T14	Outcomes 3115 3155	The incidence of laboratory and clinical
T15	Outcomes 3296 3305	pregnancy
T16	Outcomes 3310 3355	breastfeeding is safe and reduces the risk of
